CURRICULUM VITAE

Shane Edward Ruckle, M.D.

adzf1w@r.postjobfree.com

Home Address: **** **** ***** *******

Miami, FL 33138

267-***-****

Office Address: BHM Department of Emergency

**** *. ******* *****

Miami, FL 33176

Education:

01/1989-05/1992 B.S. Texas A&M University (Biomedical Sci.) 07/1992-05/1996 M.D. Texas Tech University HSC

Postgraduate Training:

07/1996-06/1997 Internship

LSU Medical Center, Baton Rouge

07/1997-06/1999 Emergency Medicine Residency

LSU Medical Center, Baton Rouge

Faculty Appointments:

07/1999-05/2000 Clinical Instructor in Emergency Medicine, Department of Emergency Medicine

University of Pennsylvania School of Medicine

06/2000-05/2006 Assistant Professor of Emergency Medicine Department of Emergency Medicine

University of Pennsylvania School of Medicine

Hospital and Administrative Appointments:

07/1999-06/2005 Attending Physician

Department of Emergency Medicine

Presbyterian Medical Center

University of Pennsylvania Health System

07/1999-06/2005 Attending Physician

Department of Emergency Medicine

Hospital of the University of Pennsylvania

University of Pennsylvania Health System

07/1999-05/2006 Attending Physician

Department of Emergency Medicine

Pennsylvania Hospital

University of Pennsylvania Health System

05/2006-05/2009 Attending Physician

Department of Emergency Medicine

Saint Vincent’s Hosptial-Manhattan

170 W. 12th Street

New York, NY 10011

06/2008-03/2011 Attending Physician

Department of Emergency Medicine

Lenox Hill Hospital

100 East 77th Street

New York, NY 10075

03/312011–present Attending Physician

Department of Emergency Medicine

Baptist Hospital

8900 N. Kendall Drive

Miami, FL 33176

Specialty Certification: 2010 - American Board of Emergency Medicine Licensure: Florida-MD

Memberships in Professional and Scientific Societies: National:

American College of Emergency Physicians

Society of Academic Emergency Medicine

American Academy of Emergency Medicine

Major Teaching and Clinical Responsibilities at the University of Pennsylvania and Affiliated Hosptitals: 1. Lecture Series for Emergency Medicine 200-300 students University of Pennsylvania School of Medicine.

2. Lecture Series for Internal Medicine residency at Pennsylvania Hospital 3. M&M Conference, Department of Emergency Medicine at Pennsylvania Hospital Clinical Reasearch:

Study: A Randomized, Multicenter, Blinded Study of the Efficacy and Safety of High-Dose (750mg), Short-Course

(3-5 days)Levofloxacin Therapy in Uncomplicated and Complicated Acute Bacterial Exacerbation of Chronic Bronchitis

Sponsor: Ortho-McNeil Pharmaceuticals

PAH Investigators: Charles V. Pollack, Jr., M.A., M.D., FACEP Susan A. Gregory, M.D., FACP, FACCP

Shane Edward Ruckle, M.D.

Paul Anthony Andrulonis, Jr., M.D.

Rationale: Levfloxacin given once daily has been studied in multiple large clinical trials and doses of 500mg once daily for seven days resulted in safe and effective treatment of ABECB. Since levofloxacin is a concentration-dependent killing antibacterial it is expected that high-dose, short course treatment will successfully treat ABECB. Several factors argue in favor of reducing therapy to the shortest duration that is effective and these include cost, improved compliance, and the total number of potential adverse events. An additional reason, however, may be equally important. Years of antibacterial use have indicated that resistance development is most closely associated with the amount of drug used. Therefore, it is expected that a higher dose, shorter course treatment will help prevent the emergence of resistance.

This is a Phase 3B protocol in which patients with both uncomplicated and complicated (the differentiation based on validated clinical criteria) acute bacterial exacerbation of chronic bronchitis (ABECB) will be studied. The primary objective of this study for the uncomplicated ABECB severity group is to establish the clinical efficacy and safety of high-dose, short-course levofloxacin compared to azithromycin. The primary objective of this study for the complicated ABECB severity group is to establish the clinical efficacy and safety of high-dose, short-course levofloxacin compared to amoxicillin/clavulanate. Study: An Epidemiological Observational Study of Deep Vein Thrombosis (DVT) Sponsor: Genecom

PAH Investigators: Charles V. Pollack, Jr., M.A., M.D., FACEP Shane Edward Ruckle, M.D.

Paul Anthony Andrulonis, Jr., M.D.

Rationale: DVT is a significant public health problem with the potential both for significant morbidity (DVT with loss of productivity, post-phlebitic syndrome) and for mortality (pulmonary embolism). This study is an epidemiological survey of approximately 7500 patients in comprehensive effort to establish a DVT registry and to study DVT and its treatment. It will provide historical data on patients, including demographic information, risk factors and prophylaxis measures. It will also provide direction for focusing the future prevention initiatives. Study: Sixteenth Multicenter Airway Research Collaboration (MARC-16) Sponsor: Abbott Pharmaceuticals

PAH Investigators: Charles V. Pollack, Jr., M.A., M.D., FACEP Shane Edward Ruckle, M.D.

Paul Anthony Andrulonis, Jr., M.D.

Rationale: Large-scale ED-based research on CAP is lacking, despite at least 2 million CAP-related visits to US EDs each year. Furthermore, much of the existing pneumonia data ignores the research questions pertinent to the ED population and the distinct characteristics of practice in this setting. These characteristics have significant impact on the use of care plans to improve care. There is a pressing need to support ED-based CAP research in a variety of topic areas, such as diagnosis and treatment (e.g., utility of diagnostic tests, accuracy of test interpretation, selection and timing of antimicrobial treatments, admission and discharge criteria), prevention (e.g., influenza vaccination and treatment), education, and economic evaluation (e.g., drug choice and health outcome, health care utilization, etc).

This study will evaluate the resistance patterns of Streptococcus pneumoniae organisms cultured in sputum samples and evaluate the clinical response to treatment with Biaxin XL. Study: Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines: The CRUSADE National Quality Improvement Initiative Sponsor: Duke Clinical Research Institute

PAH Investigators: Charles V. Pollack, Jr., M.A., M.D., FACEP Shane Edward Ruckle, M.D.

Paul Anthony Andrulonis, Jr., M.D.

Howard L. Haber, M.D., FACP, FACC

Rationale: The optimal evaluation and management strategies for patients with acute coronary syndrome who do not have ST-segment elevation continue to evolve. In response to an explosive increase in studies of these patients and their outcomes over the past several years, the American College of Cardiology (ACC) and American Heart Association (AHA) published in September of 2000 an extensive treatment guideline for these patients. Initial feedback from emergency physicians, cardiologists, and hospitals indicates that the guidelines are not being closely followed. This is particularly important in the care of patients objectively identified as being “high risk”: those with new ST-segment depression, an extended duration or accelerated pace of angina, sustained ventricular ectopy, advanced age, or with elevated cardiac troponin levels. CRUSADE is a national quality improvement initiative aimed at monitoring compliance with the ACC/AHA guidelines, for high-risk patients, over time. CRUSADE hospitals will also be offered educational materials (site reports, comparative reports, educational conferences, etc) to assist in improving compliance.

Study: A Double-Blind, Placebo-Controlled, Parallel, Multicenter Study on Extended VTE Prophylaxis in Acutely Ill Medical Patients with Prolonged Immobilization Sponsor: Aventis Pharmaceuticals

PAH Investigators: Charles V. Pollack, Jr., M.A., M.D., FACEP Susan A. Gregory, M.D., FACP, FACCP

Howard L. Haber, M.D., FACP, FACC

David C. Chang, M.D.

Dara G. Jamieson, M.D.

R. Michael Buckley, Jr., M.D.

Judy A. Somers, M.D.

Kathleen Nasci, M.D.

Paul Anthony Andrulonis, Jr., M.D.

Shane Edward Ruckle, M.D.

Rationale: VTE is a major public health concern in medically ill immobilized patients. In several other studies, LMWH has been show to significantly reduce the incidence of DVT, but it is likely that the standard treatment duration of 10+/-4 days may be too brief for some patients and that it is discontinued while they are still at risk for DVT. An extension of the prophylaxis may result in further risk reduction of VTE in medically ill patients. This study will evaluate the efficacy and safety of extended VTE prophylaxis with enoxaparin for 28+/-4 days compared to placebo, both following 10+/-4 days of initial treatment with enoxaparin. Study: Clinical Protocol for Evaluating the Distribution of Albumin Cobalt (ACB™) Test Results in Patients with Conditions Other Than Ischemic Heart Disease

Sponsor: Ischemia Technologies

PAH Investigators: Charles V. Pollack, Jr., M.A., M.D., FACEP Judy A. Somers, M.D.

Kathleen Nasci, M.D.

Paul Anthony Andrulonis, Jr., M.D.

Shane Edward Ruckle, M.D.

Rationale: There are well-accepted biochemical markers for cardiac necrosis which are used to aid in the diagnosis of myocardial infarction. However, there are no proven and accepted biochemical markers for ischemia. The Albumin Cobalt Binding Test (ACB Test™), is under investigation as a biochemical marker for ischemia. Although the sensitivity of the ACB test in detecting ischemia-modified albumin in patients with coronary ischemia appears to be high, the specificity requires further investigation. This clinical study is designed to characterize the distribution of ACB Test results in individuals with diseases other than ischemic heart disease, with particular emphasis on other ischemic conditions, and other conditions which might masquerade as ischemic heart disease or acute cardiac ischemia.

*We expect to begin this protocol in the near future. Study: A Prospective, Open-Label, Randomized, Parallel-Group Investigation to Evaluate the Safety of Enoxaparin Versus Unfractionated Heparin in Subjects who Present to the Emergency Department with Acute Coronary Syndrome

Sponsor: Aventis Pharmaceuticals

PAH Investigators: Charles V. Pollack, Jr., M.A., M.D., FACEP Shane Edward Ruckle, M.D.

Paul Anthony Andrulonis, Jr., M.D.

Rationale: This study will evaluate patients who present to the ED and are diagnosed with non-ST segment elevation ACS, including unstable angina and non-ST-segment elevation MI. Therapy for these conditions has evolved over the last decade and several studies have shown the superiority of combined antiplatelet and anticoagulant treatment over antiplatelet therapy alone. Enoxaparin has been approved in the US for prevention of ischemic complications in USA and non-Q-wave MI, but it is not widely used in the ED setting. This study will compare the efficacy and safety of enoxaparin and unfractioned heparin in this patient population.

*We expect to begin this protocol in the near future.

Contact this candidate